India — Central Drugs Standard Control Organisation

Impact: India — Central Drugs Standard Control Organisation launched risk-based inspections of drugs across six states and is analyzing samples to determine the cause of deaths.

Impact: The India — Central Drugs Standard Control Organisation is collaborating with state regulators in India to curb malpractices in the GLP-1 drug supply chain.

Impact: The India — Central Drugs Standard Control Organisation provided marketing authorization for Tanstrive, enabling its launch in India and ensuring regulatory compliance for the new drug.

Impact: The India — Central Drugs Standard Control Organisation collaborated in the development of the Drug Registry, ensuring standardization of medicine data across India's healthcare system.

Impact: The India — Central Drugs Standard Control Organisation has initiated risk-based inspections of drug manufacturing units across six states in response to the cough syrup tragedy, focusing on companies producing cough syrups, antipyretics, and antibiotics.

Impact: The India — Central Drugs Standard Control Organisation alerted the India — Drugs Control Administration, Telangana, about the adulteration of Almont-Kid Syrup, playing a crucial role in identifying the issue.

Impact: The India — Central Drugs Standard Control Organisation is involved as the draft notification for the amendments is available on its website for stakeholder comments.